Literature DB >> 7521890

Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.

M Weller1, K Frei, P Groscurth, P H Krammer, Y Yonekawa, A Fontana.   

Abstract

Fas/APO-1 is a transmembrane protein of the nerve growth factor/TNF alpha receptor family which signals apoptotic cell death in susceptible target cells. We have investigated the susceptibility of seven human malignant glioma cell lines to Fas/APO-1-dependent apoptosis. Sensitivity to Fas/APO-1 antibody-mediated cell killing correlated with cell surface expression of Fas/APO-1. Expression of Fas/APO-1 as well as Fas/APO-1-dependent cytotoxicity were augmented by preexposure of human malignant glioma cells to IFN gamma and TNF alpha. Further, pretreatment with TGF beta 2, IL1 and IL8 enhanced Fas/APO-1 antibody-induced glioma cell apoptosis whereas other cytokines including TNF beta, IL6, macrophage colony-stimulating factor, IL10 and IL13 had no such effect. None of the human malignant glioma cell lines was susceptible to TNF alpha-induced cytotoxicity. Fas/APO-1 antibody-sensitive glioma cell lines (n = 5), but not Fas/APO-1 antibody-resistant glioma cell lines (n = 2), became sensitive to TNF alpha when co-treated with inhibitors of RNA and protein synthesis. Resistance of human glioma cells to Fas/APO-1 antibody-mediated apoptosis was mainly related to low level expression of Fas/APO-1 and appeared not to be linked to overexpression of the anti-apoptotic protooncogene, bcl-2. Given the resistance of human malignant glioma to surgery, irradiation, chemotherapy and immunotherapy, we propose that Fas/APO-1 may be a promising target for a novel locoregionary approach to human malignant glioma. This strategy gains support from the demonstration of Fas/APO-1 expression in ex vivo human malignant glioma specimens and from the absence of Fas/APO-1 in normal human brain parenchyma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521890      PMCID: PMC295136          DOI: 10.1172/JCI117462

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis.

Authors:  D M Hockenbery; Z N Oltvai; X M Yin; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

2.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Authors:  T Suda; T Takahashi; P Golstein; S Nagata
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

3.  Astrocytes present myelin basic protein to encephalitogenic T-cell lines.

Authors:  A Fontana; W Fierz; H Wekerle
Journal:  Nature       Date:  1984 Jan 19-25       Impact factor: 49.962

4.  Antigen presentation and tumor cytotoxicity by interferon-gamma-treated microglial cells.

Authors:  K Frei; C Siepl; P Groscurth; S Bodmer; C Schwerdel; A Fontana
Journal:  Eur J Immunol       Date:  1987-09       Impact factor: 5.532

5.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

Authors:  F Leithäuser; J Dhein; G Mechtersheimer; K Koretz; S Brüderlein; C Henne; A Schmidt; K M Debatin; P H Krammer; P Möller
Journal:  Lab Invest       Date:  1993-10       Impact factor: 5.662

6.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.

Authors:  A Oehm; I Behrmann; W Falk; M Pawlita; G Maier; C Klas; M Li-Weber; S Richards; J Dhein; B C Trauth
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

7.  Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.

Authors:  A Fontana; H Hengartner; N de Tribolet; E Weber
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

8.  Effects of recombinant human tumor necrosis factor-alpha on the surface phenotype and the growth of human malignant glioma cell lines.

Authors:  P Zuber; R S Accolla; S Carrel; A C Diserens; N de Tribolet
Journal:  Int J Cancer       Date:  1988-11-15       Impact factor: 7.396

9.  Fas transduces activation signals in normal human T lymphocytes.

Authors:  M R Alderson; R J Armitage; E Maraskovsky; T W Tough; E Roux; K Schooley; F Ramsdell; D H Lynch
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

10.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.

Authors:  S Yonehara; A Ishii; M Yonehara
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  62 in total

1.  Induction of apoptosis in glioma cells by molecules released from activated macrophages.

Authors:  George G Chen; Ying S Chu; Ernest C W Chak; Billy C S Leung; Wai S Poon
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

Review 2.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

3.  APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.

Authors:  Günter Eisele; Patrick Roth; Kathy Hasenbach; Steffen Aulwurm; Fabian Wolpert; Ghazaleh Tabatabai; Wolfgang Wick; Michael Weller
Journal:  Neuro Oncol       Date:  2010-12-22       Impact factor: 12.300

4.  IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Authors:  J M Wigginton; E Gruys; L Geiselhart; J Subleski; K L Komschlies; J W Park; T A Wiltrout; K Nagashima; T C Back; R H Wiltrout
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

5.  Humoral immune response to p53 in malignant glioma.

Authors:  M Weller; A Bornemann; M Ständer; M Schabet; J Dichgans; R Meyermann
Journal:  J Neurol       Date:  1998-03       Impact factor: 4.849

Review 6.  Apoptosis in neural development and disease.

Authors:  N D Mazarakis; A D Edwards; H Mehmet
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-11       Impact factor: 5.747

7.  Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway.

Authors:  D Ashany; X Song; E Lacy; J Nikolic-Zugic; S M Friedman; K B Elkon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression.

Authors:  Bruce Frankel; Sharon L Longo; Christopher Leach; Gregory W Canute; Timothy C Ryken
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

9.  Caspase-1 mediates Fas-induced apoptosis and is up-regulated by interferon-gamma in human astrocytoma cells.

Authors:  Chulhee Choi; Eunjoo Jeong; Etty N Benveniste
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

10.  Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interleukin-2.

Authors:  U Herrlinger; R Buchholz; P Jachimczak; M Schabet
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.